Clinical Trials Logo

Esophagus Cancer clinical trials

View clinical trials related to Esophagus Cancer.

Filter by:

NCT ID: NCT03342937 Completed - Gastric Cancer Clinical Trials

KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer

Start date: January 11, 2018
Phase: Phase 2
Study type: Interventional

This study will be conducted in two stages: 1) safety validation and 2) dose expansion 1. Safety Validation Cohort: The first portion of the study will preliminarily establish the tolerability of the combination of pembrolizumab, oxaliplatin and capecitabine. Five (5) subjects will be enrolled and their safety data after 21 days of treatment will be reviewed before additional subjects are enrolled. Subjects on this portion of the study will only be enrolled at the Duke Cancer Institute. 2. Dose Expansion Cohort: The second portion of the study (ie. phase II) will enroll 30 subjects. In the dose expansion cohort, the first cycle will be modified to allow one week of pembrolizumab monotherapy before starting capecitabine and oxaliplatin (XELOX) chemotherapy, which will allow analysis of biomarkers related to pembrolizumab. Subjects on this portion of the study will be enrolled at the Duke Cancer institute and select external collaborating institutions. The primary objective of this trial is to describe the progression free survival (PFS) associated with the combination of pembrolizumab, oxaliplatin and capecitabine (pembrolizumab +XELOX) in all patients with previously untreated metastatic esophagogastric adenocarcinoma.

NCT ID: NCT03332433 Completed - Gastric Cancer Clinical Trials

High-flow Nasal Cannula Oxygenation Decrease Hypoxia in Gastroscopy Sedated by Propofol

HONCHO
Start date: November 10, 2017
Phase: N/A
Study type: Interventional

Hypoxia is the most common adverse events during sedated gastroscopy. In present study, high-flow nasal cannula oxygenation will be utilized in order to reduce the hypoxia. At the same time the feasibility and safety will be evaluated.

NCT ID: NCT03298204 Completed - Chemotherapy Effect Clinical Trials

Definitive (Chemo)Radiotherapy for Patients With Esophageal Cancer - 3JECROG R-01

Start date: June 1, 2017
Phase:
Study type: Observational

The aim of this observational study is to retrospectively collect survival data for 3000 primary esophageal cancer patients from multicenter between January 2000 to present. Based on a Cox model, we want to develope a nomogram that predicts local recurrence, distant metastases, and survival for patients treated with radiotherapy or chemoradiotherapy with or without chemotherapy.

NCT ID: NCT03245736 Completed - Prostate Cancer Clinical Trials

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Start date: August 23, 2017
Phase: Phase 2
Study type: Interventional

The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.

NCT ID: NCT03237130 Completed - Esophagus Cancer Clinical Trials

Prediction of Lymphatic Metastasis in Esophageal Cancer by CT Radiomics

Start date: February 15, 2017
Phase:
Study type: Observational

This study proposes to establish a CT radiomics-based prediction model for identifying metastasis lymph nodes in esophageal cancer.

NCT ID: NCT03199586 Completed - Breast Cancer Clinical Trials

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Start date: December 21, 2017
Phase: Phase 1
Study type: Interventional

Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.

NCT ID: NCT02979691 Completed - Esophagus Cancer Clinical Trials

Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01

Start date: October 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Ratiotherapy alone is the current standard treatment for elderly esophageal or esophagogastric cancer in China. And Little is known about chemoradiotherapy (CRT) in elderly patients. This study aimed to assess the efficiency and safety of simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) with S1 based SIB-IMRT followed by adjuvant chemotherapy with S1 in in elderly (age ≥70 years) esophageal or esophagogastric cancer patients

NCT ID: NCT02879227 Completed - Esophagus Cancer Clinical Trials

Radiochemotherapy in Elderly Patients With Oesophagus Cancer

Chronos
Start date: January 2010
Phase: Phase 2
Study type: Interventional

Phase II study of radiochemotherapy for elderly patients with oesophagus cancer.

NCT ID: NCT02552121 Completed - Bladder Cancer Clinical Trials

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Start date: November 30, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the trial is to establish the tolerability of tisotumab vedotin (HuMax-TF-ADC) dosed three times every four weeks (3q4wk) in a mixed population of patients with specified solid tumors.

NCT ID: NCT02001623 Completed - Bladder Cancer Clinical Trials

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Start date: November 30, 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.